News 23andMe ends drug development and slashes staff 23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.
News Tarsus places $800m wager on Alkeus' Stargardt therapy Tarsus agrees to buy Alkeus in an $800m deal that will give it rights to a drug for eye disorder Stargardt disease with "blockbuster potential."
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.